Global Community

Palantir's Q2 2026 was genuinely extraordinary: revenue of $1.935 billion grew 93% year over year, US commercial revenue grew 149%, and the company raised full-year guidance to roughly $8.15 billion, about 82% growth. That part of the story is real and it is the reason to be interested.Read more

Catalysts The main catalyst for PetroTal is the restart of drilling at the Bretaña field. Production has fallen heavily over the last year.Read more

A constructive long-term outlook supported by trend structure, key moving averages, and breakout potential. Overview Robo.ai (AIIO) has developed from a speculative micro-cap name into a more technically structured growth candidate.Read more

If gold prices rise a lot, STLLR Gold could look very different because its large gold resource base becomes far more valuable. The key question is whether investors treat it like a real producer with a value tied to what it can pull out of the ground—or just a pile of ounces on paper.Read more

领先的可负担房屋及综合城镇开发商Lagenda Properties Berhad（KLSE: LAGENDA、7179）在2025财政年交出了非常亮眼的业绩！ 突破10亿令吉营收大关 LAGENDA全年营收首次超过10亿令吉，达到1.06亿令吉，净利润为1.795亿令吉。 更重要的是，年度销售额达到了创纪录的17亿令吉，同比增长50.0%，并超越了管理层设定的15亿令吉目标。在房地产市场整体更为谨慎的背景下，能够如此大规模地超越内部销售指引，表明其需求能见度依然完好。 柔佛州崭露头角，成为关键盈利驱动力 强劲的需求遍布雪兰莪、彭亨和柔佛州，其中柔佛州贡献了2025财年总销售额的近一半。La Lumiére（古来）、Lagenda Ardea（Ulu Bernam）和 La' Indera（关丹）等项目是主要的销售功臣。 从投资组合配置的角度来看，柔佛州日益增长的贡献具有战略意义。该州正受益于经济活动的改善和跨境动态。 2025财年第四季：增长伴随利润率稳定 在2025财年第四季，得益于霹雳、柔佛和雪兰莪项目的工程进度认证增加，营收同比增长27.2%至2.974亿令吉。税前利润增长7.1%至6420万令吉。 然而，净利润同比微降1.1%至4500万令吉。这一轻微下滑并不令人担忧，更可能反映的是项目组合和时间差问题，而非结构性利润率压力。运营执行保持稳定，盈利状况继续得到稳固的销售转化支撑。 具吸引力的股息 LAGENDA宣布派发每股3.5仙的第二次中期股息，总额达2910万令吉。 这使得2025财年的总股息达到每股6.5仙，相当于总派息额5420万令吉，基于2025财年净利润计算的股息支付率为30.2%。 请注意，除息日定于2026年4月15日，付款日期定于2026年5月18日。 展望 LAGENDA以创纪录的16亿令吉未入账销售额进入2026财年，为来年提供了坚实的盈利能见度。该公司的增长轨迹还得到了占地4300英亩、估计总发展值达110亿令吉的大量地库的进一步支持，这提供了多年的开发潜力。 展望未来，管理层计划在吉打州的双溪大年和森美兰州的芙蓉新城推出新的城镇开发项目。这些新项目将拓宽其地理足迹，并强化其可扩展的城镇开发模式，使LAGENDA能够在维持增长势头的同时，巩固其作为马来西亚领先的可负担房屋城镇开发商的地位。Read more

Rhythm Pharmaceuticals is turning a rare genetic obesity medicine into a broader set of uses, and early demand looks stronger than expected as more doctors start prescribing it. On top of that, recent deal activity in similar drug areas suggests the company could become more attractive to a buyer if it keeps executing.Read more

FreightCar America shifts production to a large, lower-cost factory in northern Mexico and now says the hard part of its turnaround is largely behind it. If demand stays steady and the company keeps cleaning up past financing baggage, it could keep taking customers from higher-cost rivals—but the earlier transition shows the risks if conditions change.Read more

Lucky Cement’s recent results look stronger than they first seem, driven by rising local demand and real cost cuts rather than one-off accounting boosts. With new capacity coming online overseas and earnings help from its power, chemicals, and auto businesses, the market may be underestimating how much runway it still has.Read more

Novo Nordisk’s weight-loss medicines turn a diabetes specialist into a cultural and medical heavyweight, and the company now races to expand factories and develop the next wave of treatments. The bigger question is whether new rivals and tougher rules could slow the momentum—or whether this recent pullback is a rare chance to buy into a business with years of demand ahead.Read more